Zachary Scheiner - 11 Jun 2025 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Role: Director
Signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact
Issuer symbol: LENZ
Transactions as of: 11 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 11 Jun 2025, 17:45:50 UTC
Previous filing: 09 Jun 2025
Next filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Scheiner Zachary	Director	C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE, SUITE 300, SOLANA BEACH	/s/ Daniel R. Chevallard, as Attorney-in-Fact	11 Jun 2025	0001816523

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LENZ	Stock Option (right to buy)	Award	$0	+13,500		$0.000000	13,500	11 Jun 2025	Common Stock	13,500	$30.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Content

Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Remarks:

Exhibit 24 - Power of Attorney